INDUSTRY OVERVIEW
The Theranostics is Growing at 13.50% and is expected to reach 22.5Billion by 2033. Below mentioned are some of the dynamics shaping the Theranostics.Theranostics Market Size in (USD Billion) CAGR Growth Rate 13.50%
| Study Period | 2020-2033 |
| Market Size (2024): | 10.7Billion |
| Market Size (2033): | 22.5Billion |
| CAGR (2024 - 2033): | 13.50% |
| Fastest Growing Region | Europe |
| Dominating Region | North America |
www.htfmarketinsights.com
Theranostics is a field of medicine that combines diagnostic imaging and targeted therapy, enabling more precise treatments. It utilizes nanoparticles and molecular imaging agents to detect diseases early and deliver therapies directly to the affected areas. In oncology, theranostics has gained significant attention for enabling personalized cancer treatment, improving outcomes while reducing side effects. The market is expected to grow as more diagnostic and therapeutic tools are integrated into personalized medicine.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Regulatory Landscape
- Regulations governing the use of theranostic agents, safety standards, and clinical trial requirements are shaping the development of these combined diagnostic-therapeutic systems.
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- Rising Demand For Personalized Therapies
- Technological Advancements In Imaging
- Growth Of Precision Medicine
- Increasing Regulatory Support For Novel Therapeutics
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- High Development Costs
- Regulatory Challenges In Approvals
- Lack Of Standardized Diagnostic Protocols
- Patient Access Issues
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Growth In Personalized Imaging Agents
- Use Of Targeted Therapeutics
- Integration Of AI In Theranostics
- Use Of Radiopharmaceuticals In Cancer Therapy
Market Opportunities:
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Growth Of Targeted Cancer Therapies
- Expansion Of Radiopharmaceutical Markets
- Use Of Theranostics In Neurological Diseases
- Investment In AI-Powered Imaging Solutions
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Diagnostic Imaging
- Targeted Drug Delivery
- Imaging Agents
- Molecular Imaging
Theranostics Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Oncology
- Neurology
- Cardiovascular
- Infectious Diseases
- Immunology
Theranostics Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Europe is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Europe
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Roche (Switzerland)
- Siemens Healthineers (Germany)
- GE Healthcare (US)
- Thermo Fisher Scientific (US)
- Philips Healthcare (Netherlands)
- Abbott Laboratories (US)
- Novartis (Switzerland)
- Becton Dickinson (US)
- Bio-Rad Laboratories (US)
- Medtronic (Ireland)
- Merck (US)
- Johnson & Johnson (US)
- Eli Lilly (US)
- Bayer (Germany)
Theranostics Market Segmentation by Players
www.htfmarketinsights.com
Regional Analysis
- Theranostics, which combines therapy and diagnostics, is growing rapidly in North America and Europe, particularly for personalized medicine in oncology.
Market Entropy
- June 2025 – GE Healthcare and Siemens launched theranostic platforms integrating diagnostics and treatment, offering personalized medicine solutions for cancer care globally.
Merger & Acquisition
- March 2023: TheranoTech Solutions merged with MedDiagnostics, providing integrated theranostics solutions for personalized diagnostics and treatment options.
Regulatory Landscape
- Regulations governing the use of theranostic agents, safety standards, and clinical trial requirements are shaping the development of these combined diagnostic-therapeutic systems.
Patent Analysis
- Patents focus on the development of theranostic agents that can simultaneously diagnose and treat diseases, particularly cancer, using nanoparticles and targeted therapy.
Investment and Funding Scenario
- Investment in theranostics is increasing, driven by the growing demand for personalized treatments that can deliver precise therapeutic outcomes while also monitoring disease progression.
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2024 |
|
Based Year Market Size (2023) |
10.7Billion |
|
Historical Period |
2020 to 2024 |
|
CAGR (2024 to 2033) |
13.50% |
|
Forecast Period |
2024 to 2033 |
|
Forecasted Period Market Size (2033) |
22.5Billion |
|
Scope of the Report |
Segmentation by Type Diagnostic Imaging,Targeted Drug Delivery,Imaging Agents,Molecular Imaging, Segmentation by Application Oncology,Neurology,Cardiovascular,Infectious Diseases,Immunology, Sales Channel |
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Roche (Switzerland),Siemens Healthineers (Germany),GE Healthcare (US),Thermo Fisher Scientific (US),Philips Healthcare (Netherlands),Abbott Laboratories (US),Novartis (Switzerland),Becton Dickinson (US),Bio-Rad Laboratories (US),Medtronic (Ireland),Merck (US),Johnson & Johnson (US),Eli Lilly (US),Bayer (Germany) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Theranostics - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Theranostics Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Theranostics Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Theranostics Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 Rising Demand For Personalized Therapies
- 3.1.2 Technological Advancements In Imaging
- 3.1.3 Growth Of Precision Medicine
- 3.1.4 Increasing Regulatory Support For Novel Therapeutics
-
3.2 Available Opportunities
- 3.2.1 Growth Of Targeted Cancer Therapies
- 3.2.2 Expansion Of Radiopharmaceutical Markets
- 3.2.3 Use Of Theranostics In Neurolo
-
3.3 Influencing Trends
- 3.3.1 Growth In Personalized Imaging Agents
- 3.3.2 Use Of Targeted Therapeutics
- 3.3.3 Integration Of AI In Theranostics
- 3.3.4 Use Of
-
3.4 Challenges
- 3.4.1 High Development Costs
- 3.4.2 Regulatory Challenges In Approvals
- 3.4.3 Lack Of Standardized Diagnostic Protocols
- 3.4.4 Patient
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Theranostics Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Theranostics Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Theranostics : Competition Benchmarking & Performance Evaluation
- 5.1 Global Theranostics Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Theranostics Revenue 2024
- 5.3 Global Theranostics Sales Volume by Manufacturers (2024)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 FPNV Positioning Matrix
- 5.6 Heat Map Analysis
Chapter 6: Global Theranostics Market: Company Profiles
- 6.1 Roche (Switzerland)
- 6.1.1 Roche (Switzerland) Company Overview
- 6.1.2 Roche (Switzerland) Product/Service Portfolio & Specifications
- 6.1.3 Roche (Switzerland) Key Financial Metrics
- 6.1.4 Roche (Switzerland) SWOT Analysis
- 6.1.5 Roche (Switzerland) Development Activities
- 6.2 Siemens Healthineers (Germany)
- 6.3 GE Healthcare (US)
- 6.4 Thermo Fisher Scientific (US)
- 6.5 Philips Healthcare (Netherlands)
- 6.6 Abbott Laboratories (US)
- 6.7 Novartis (Switzerland)
- 6.8 Becton Dickinson (US)
- 6.9 Bio-Rad Laboratories (US)
- 6.10 Medtronic (Ireland)
- 6.11 Merck (US)
- 6.12 Johnson & Johnson (US)
- 6.13 Eli Lilly (US)
- 6.14 Bayer (Germany)
- 6.15 Sanofi (France)
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Theranostics by Type & Application (2020-2033)
-
7.1 Global Theranostics Market Revenue Analysis (USD Million) by Type (2020-2024)
- 7.1.1 Diagnostic Imaging
- 7.1.2 Targeted Drug Delivery
- 7.1.3 Imaging Agents
- 7.1.4 Molecular Imaging
- 7.1.5 Personalized Medicine
-
7.2 Global Theranostics Market Revenue Analysis (USD Million) by Application (2020-2024)
- 7.2.1 Oncology
- 7.2.2 Neurology
- 7.2.3 Cardiovascular
- 7.2.4 Infectious Diseases
- 7.2.5 Immunology
- 7.3 Global Theranostics Market Revenue Analysis (USD Million) by Type (2024-2033)
- 7.4 Global Theranostics Market Revenue Analysis (USD Million) by Application (2024-2033)
Chapter 8 : North America Theranostics Market Breakdown by Country, Type & Application
- 8.1 North America Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 8.2.1 Diagnostic Imaging
- 8.2.2 Targeted Drug Delivery
- 8.2.3 Imaging Agents
- 8.2.4 Molecular Imaging
- 8.2.5 Personalized Medicine
-
8.3 North America Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 8.3.1 Oncology
- 8.3.2 Neurology
- 8.3.3 Cardiovascular
- 8.3.4 Infectious Diseases
- 8.3.5 Immunology
- 8.4 North America Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 8.5 North America Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 8.6 North America Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Theranostics Market Breakdown by Country, Type & Application
- 9.1 LATAM Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 9.2.1 Diagnostic Imaging
- 9.2.2 Targeted Drug Delivery
- 9.2.3 Imaging Agents
- 9.2.4 Molecular Imaging
- 9.2.5 Personalized Medicine
-
9.3 LATAM Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 9.3.1 Oncology
- 9.3.2 Neurology
- 9.3.3 Cardiovascular
- 9.3.4 Infectious Diseases
- 9.3.5 Immunology
- 9.4 LATAM Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 9.5 LATAM Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 9.6 LATAM Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 10 : West Europe Theranostics Market Breakdown by Country, Type & Application
- 10.1 West Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 10.2.1 Diagnostic Imaging
- 10.2.2 Targeted Drug Delivery
- 10.2.3 Imaging Agents
- 10.2.4 Molecular Imaging
- 10.2.5 Personalized Medicine
-
10.3 West Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 10.3.1 Oncology
- 10.3.2 Neurology
- 10.3.3 Cardiovascular
- 10.3.4 Infectious Diseases
- 10.3.5 Immunology
- 10.4 West Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 10.5 West Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 10.6 West Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 11 : Central & Eastern Europe Theranostics Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 11.2.1 Diagnostic Imaging
- 11.2.2 Targeted Drug Delivery
- 11.2.3 Imaging Agents
- 11.2.4 Molecular Imaging
- 11.2.5 Personalized Medicine
-
11.3 Central & Eastern Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 11.3.1 Oncology
- 11.3.2 Neurology
- 11.3.3 Cardiovascular
- 11.3.4 Infectious Diseases
- 11.3.5 Immunology
- 11.4 Central & Eastern Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 11.5 Central & Eastern Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 11.6 Central & Eastern Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 12 : Northern Europe Theranostics Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 12.2.1 Diagnostic Imaging
- 12.2.2 Targeted Drug Delivery
- 12.2.3 Imaging Agents
- 12.2.4 Molecular Imaging
- 12.2.5 Personalized Medicine
-
12.3 Northern Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 12.3.1 Oncology
- 12.3.2 Neurology
- 12.3.3 Cardiovascular
- 12.3.4 Infectious Diseases
- 12.3.5 Immunology
- 12.4 Northern Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 12.5 Northern Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 12.6 Northern Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 13 : Southern Europe Theranostics Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 13.2.1 Diagnostic Imaging
- 13.2.2 Targeted Drug Delivery
- 13.2.3 Imaging Agents
- 13.2.4 Molecular Imaging
- 13.2.5 Personalized Medicine
-
13.3 Southern Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 13.3.1 Oncology
- 13.3.2 Neurology
- 13.3.3 Cardiovascular
- 13.3.4 Infectious Diseases
- 13.3.5 Immunology
- 13.4 Southern Europe Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 13.5 Southern Europe Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 13.6 Southern Europe Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 14 : East Asia Theranostics Market Breakdown by Country, Type & Application
- 14.1 East Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 14.2.1 Diagnostic Imaging
- 14.2.2 Targeted Drug Delivery
- 14.2.3 Imaging Agents
- 14.2.4 Molecular Imaging
- 14.2.5 Personalized Medicine
-
14.3 East Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 14.3.1 Oncology
- 14.3.2 Neurology
- 14.3.3 Cardiovascular
- 14.3.4 Infectious Diseases
- 14.3.5 Immunology
- 14.4 East Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 14.5 East Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 14.6 East Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 15 : Southeast Asia Theranostics Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 15.2.1 Diagnostic Imaging
- 15.2.2 Targeted Drug Delivery
- 15.2.3 Imaging Agents
- 15.2.4 Molecular Imaging
- 15.2.5 Personalized Medicine
-
15.3 Southeast Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 15.3.1 Oncology
- 15.3.2 Neurology
- 15.3.3 Cardiovascular
- 15.3.4 Infectious Diseases
- 15.3.5 Immunology
- 15.4 Southeast Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 15.5 Southeast Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 15.6 Southeast Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 16 : South Asia Theranostics Market Breakdown by Country, Type & Application
- 16.1 South Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 16.2.1 Diagnostic Imaging
- 16.2.2 Targeted Drug Delivery
- 16.2.3 Imaging Agents
- 16.2.4 Molecular Imaging
- 16.2.5 Personalized Medicine
-
16.3 South Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 16.3.1 Oncology
- 16.3.2 Neurology
- 16.3.3 Cardiovascular
- 16.3.4 Infectious Diseases
- 16.3.5 Immunology
- 16.4 South Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 16.5 South Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 16.6 South Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 17 : Central Asia Theranostics Market Breakdown by Country, Type & Application
- 17.1 Central Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 17.2.1 Diagnostic Imaging
- 17.2.2 Targeted Drug Delivery
- 17.2.3 Imaging Agents
- 17.2.4 Molecular Imaging
- 17.2.5 Personalized Medicine
-
17.3 Central Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 17.3.1 Oncology
- 17.3.2 Neurology
- 17.3.3 Cardiovascular
- 17.3.4 Infectious Diseases
- 17.3.5 Immunology
- 17.4 Central Asia Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 17.5 Central Asia Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 17.6 Central Asia Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 18 : Oceania Theranostics Market Breakdown by Country, Type & Application
- 18.1 Oceania Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 18.2.1 Diagnostic Imaging
- 18.2.2 Targeted Drug Delivery
- 18.2.3 Imaging Agents
- 18.2.4 Molecular Imaging
- 18.2.5 Personalized Medicine
-
18.3 Oceania Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 18.3.1 Oncology
- 18.3.2 Neurology
- 18.3.3 Cardiovascular
- 18.3.4 Infectious Diseases
- 18.3.5 Immunology
- 18.4 Oceania Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 18.5 Oceania Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 18.6 Oceania Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 19 : MEA Theranostics Market Breakdown by Country, Type & Application
- 19.1 MEA Theranostics Market by Country (USD Million) & Sales Volume (Units) [2020-2024]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Theranostics Market by Type (USD Million) & Sales Volume (Units) [2020-2024]
- 19.2.1 Diagnostic Imaging
- 19.2.2 Targeted Drug Delivery
- 19.2.3 Imaging Agents
- 19.2.4 Molecular Imaging
- 19.2.5 Personalized Medicine
-
19.3 MEA Theranostics Market by Application (USD Million) & Sales Volume (Units) [2020-2024]
- 19.3.1 Oncology
- 19.3.2 Neurology
- 19.3.3 Cardiovascular
- 19.3.4 Infectious Diseases
- 19.3.5 Immunology
- 19.4 MEA Theranostics Market by Country (USD Million) & Sales Volume (Units) [2025-2033]
- 19.5 MEA Theranostics Market by Type (USD Million) & Sales Volume (Units) [2025-2033]
- 19.6 MEA Theranostics Market by Application (USD Million) & Sales Volume (Units) [2025-2033]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Theranostics market is expected to see value worth 10.7 Billion in 2024.
The Theranostics Market is growing at a CAGR of 13.50% over the forecasted period 2024 - 2033.
The changing dynamics and trends such as Growth In Personalized Imaging Agents,Use Of Targeted Therapeutics,Integration Of AI In Theranostics,Use Of Radiopharmaceuticals In Cancer Therapy,Adoption Of Non-Invasive Diagnostic Methods Are Trends. are seen as major Game Changer in Global Theranostics Market.
- Rising Demand For Personalized Therapies
- Technological Advancements In Imaging
- Growth Of Precision Medicine
- Increasing Regulatory Support For Novel Therapeutics
- Rising Prevalence Of Chronic Diseases Drive Market Growth.
As Industry players prepare to scale up, Theranostics Market sees major concern such as High Development Costs,Regulatory Challenges In Approvals,Lack Of Standardized Diagnostic Protocols,Patient Access Issues,Complex Integration Of Diagnostic & Therapeutic Tools Present Challenges..
Some of the opportunities that Analyst at HTF MI have identified in Theranostics Market are:
- Growth Of Targeted Cancer Therapies
- Expansion Of Radiopharmaceutical Markets
- Use Of Theranostics In Neurological Diseases
- Investment In AI-Powered Imaging Solutions
- Growth In Personalized Medicine Programs Present Opportunities.
New entrants, including competitors from unrelated industries along with players such as Roche (Switzerland),Siemens Healthineers (Germany),GE Healthcare (US),Thermo Fisher Scientific (US),Philips Healthcare (Netherlands),Abbott Laboratories (US),Novartis (Switzerland),Becton Dickinson (US),Bio-Rad Laboratories (US),Medtronic (Ireland),Merck (US),Johnson & Johnson (US),Eli Lilly (US),Bayer (Germany),Sanofi (France) Instituting a robust process in Global Theranostics Market.
Research paper of Global Theranostics Market shows that companies are making better progress than their supply chain peers –including suppliers, majorly in end-use applications such as Oncology,Neurology,Cardiovascular,Infectious Diseases,Immunology.
The Global Theranostics Market Study is segmented by Diagnostic Imaging,Targeted Drug Delivery,Imaging Agents,Molecular Imaging,Personalized Medicine.
The Global Theranostics Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
Historical Year: 2020 - Base year: 2024. Forecast period**: 2025 to 2033 [** unless otherwise stated]
Theranostics is a field of medicine that combines diagnostic imaging and targeted therapy, enabling more precise treatments. It utilizes nanoparticles and molecular imaging agents to detect diseases early and deliver therapies directly to the affected areas. In oncology, theranostics has gained significant attention for enabling personalized cancer treatment, improving outcomes while reducing side effects. The market is expected to grow as more diagnostic and therapeutic tools are integrated into personalized medicine.
